| アブストラクト | Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment but are responsible for various immune-related adverse events (irAE). The impact of non-anticancer medications (comedications) on irAE occurrence remains largely unexplored. The objective of this study was to assess comedications associated with an increased reporting of irAE with ICIs. In this pharmacovigilance study, all individual case safety reports (ICSRs) involving ICIs reported in the World Health Organization international pharmacovigilance database Vigibase up to January 2024 were extracted. All suspect or interacting comedications were analyzed individually and as drug classes using Anatomical Therapeutic Chemical classification level 4. The primary outcome was the reporting odds ratio (ROR) of irAE in patients who received both an ICI and the comedication of interest, compared with ICI-treated patients who did not receive that comedication. Among 169,753 ICSRs involving an ICI, a total of 314,366 comedications were recorded, with 8,122 identified as "suspect or interacting." Analysis shows an increased reporting of nephritis with proton pump inhibitors (PPI) (ROR = 29.62 [95% CI = 18.61-47.14]) and with non-steroidal anti-inflammatory drugs (ROR = 10.47 [95% CI = 4.15-26.41]), myositis with statins (ROR = 9.41 [95% CI = 3.50-25.30]), ketoconazole with hepatitis (ROR = 20.49 [95% CI = 1.53-274.17]) and autoimmune bullous disease with dipeptyl-peptidase-4 inhibitors (ROR = 46.42 [95% CI = 11.71-184.05]), among others. Various drugs, including PPI (ROR = 8.61 [95% CI = 3.48-21.26]), some anti-infectives (sulfamethoxazole, ROR = 31.31 [95% CI = 13.32-73.61], clavulanic acid, ROR = 18.12 [95% CI = 4.77-68.89]), allopurinol (ROR = 57.11 [95% CI = 11.27-289.39]) or levetiracetam (ROR = 14.91 [95% CI = 2.15-103.64]) were associated with serious cutaneous adverse reactions. Complementary analysis showed higher ROR in the ICI population versus without ICI for the association of nephritis with ibuprofen (ROR(ICI) = 27.82 vs. ROR(VigiBaseWithoutICI) = 3.56, ROR(ratio) = 7.81 [95% CI = 1.23-49.50]) and myocarditis with influenza vaccine (ROR(ICI) = 22.74 vs. ROR(VigiBaseWithoutICI) = 0.66, ROR(ratio) = 34.45 [95% CI = 1.66-723.24]), suggesting a synergistic toxicity. This study identified multiple comedications associated with an increased reporting of specific irAE. Some of them might be synergistic warranting further investigation. |
|---|
| 投稿者 | Laurent, Leonard; Abbar, Baptiste; Bihan, Kevin; Dumas, Elise; Jochum, Floriane; Lebrun-Vignes, Benedicte; Spano, Jean-Philippe; Salem, Joe-Elie; Hamy, Anne-Sophie; Reyal, Fabien; Gougis, Paul |
|---|
| 組織名 | Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity;and Cancer, Institut Curie, Universite Paris Cite, Paris, France.;Department of Medical Oncology, Pitie-Salpetriere Hospital, Sorbonne Universite,;Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.;Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Inserm U1135,;Sorbonne Universite, Paris, France.;Department of PharmacologyInstitut National de la Sante et de la Recherche;Medicale (INSERM), Assistance Publique - Hopitaux de Paris (AP-HP), Clinical;Investigation Center (CIC-1901), Regional Pharmacovigilance Centre,;Pitie-Salpetriere Hospital, Sorbonne Universite, Paris, France.;Department of Mathematics, Ecole Polytechnique Federale de Lausanne, Lausanne,;Switzerland.;Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.;Department of Medical Oncology, Institut Curie, Universite Paris Cite, Paris,;France.;Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie,;Universite Paris Cite, Paris, France.;Department of Surgical Oncology, Institut Godinot, Reims, France. |
|---|
